Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Barcelona, Spain – 29 Aug 2017: PCSK9 inhibitors do not increase short-term risk of type 2 diabetes, suggests a meta-analysis in more than 68 000 patients presented at ESC Congress today. (1)Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are novel drugs used to control low-density lipoprotein (LDL) cholesterol (the “bad” cholesterol), potentially reducing it by 50–60%. These monoclonal antibodies have been considered breakthrough technologies since they can successfully treat patients intolerant to statins and patients with familial hypercholesterolaemia, a genetic disorder characterised by high levels of LDL cholesterol.LDL cholesterol reduction with statins and PCSK9 inhibitors dramatically reduces the risk of cardiovascular disease. Similarly to statins, however, PCSK9 inhibitors could interfere with insulin production, thereby causing diabetes.“Genetic mutations in the PCSK9 gene are associated with incident diabetes,” said lead author Dr Luiz Sérgio Carvalho, clinical investigator, Laboratory of Atherosclerosis and Vascular Biology (AtheroLab), University of Campinas (UNICAMP), São Paulo, Brazil. “We therefore hypothesised that treatment with PCSK9 inhibitors could lead to the development of type 2 diabetes.”To evaluate this hypothesis, the researchers systematically reviewed all published randomised clinical trials comparing PCSK9 inhibitors with placebo in patients with primary hypercholesterolaemia. Study characteristics, quality, and data were independently assessed by two reviewers. The primary outcome measures were plasma glycosylated haemoglobin (HbA1c), fasting blood glucose, or a new diagnosis of type 2 diabetes mellitus.A meta-analysis was conducted in 20 randomised clinical trials with 68 123 participants. The mean follow-up of the trials was 42 weeks and the median follow-up was 48 weeks. The mean age of patients was 60 years, 58% were male, and at baseline fasting blood glucose was 103 mg/dL and HbA1c was 5.89%.The investigators found that compared to placebo, PCSK9 inhibitors were associated with significant increases in fasting blood glucose of around 2% per year and in HbA1c of approximately 0.05% per year. The relative risk of incident type 2 diabetes with PCSK9 inhibitors compared to placebo was 1.04 (95% confidence interval, 0.96–1.13).“The small changes in fasting blood glucose and HbA1c in the short-term were not sufficient to increase the incidence of type 2 diabetes,” said Dr Carvalho.Nevertheless, in exploratory (meta-regression) analyses adjusted for age and gender, there was a trend towards an increased risk of type 2 diabetes in patients who experienced more intense LDL cholesterol reduction (lowering by 55% or more) and those who were treated with PCSK9 inhibitors for more than one year.Dr Carvalho said: “We found that treatment with PCSK9 inhibitors is associated with a small but significant increase in plasma glycaemia and HbA1c, without increasing the risk of incident type 2 diabetes in the short-term. If these drugs are found to have a small or even moderate diabetogenic effect in the long-term, it is unlikely to change prescribing guidelines given their substantial benefit in reducing cardiovascular risk.”ENDS
Sources of funding: The study was sponsored by the State University of Campinas (UNICAMP).
Disclosures: The authors have nothing to disclose.
Acknowledgements: The authors thank the staff from UNICAMP’s Laboratory of Atherosclerosis and Vascular Biology (AtheroLab) for the technical support.
References and notes
(1) The abstract “Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes mellitus: a systematic review and meta-analysis with over 10,000 patients” will be presented during:
ESC Press OfficeFor more information, please contact the ESC Press Office: firstname.lastname@example.org.For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856The press conference timetable is available here.
To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. About the European Society of CardiologyThe European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.About ESC Congress 2017ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at email@example.com.This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved